{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:54:16Z","timestamp":1792450456979,"version":"4.5.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.iac.2014.01.012","type":"journal-article","created":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T07:31:09Z","timestamp":1395041469000},"page":"433-447","source":"Crossref","is-referenced-by-count":53,"title":["Treatment Strategies in Mastocytosis"],"prefix":"10.1016","volume":"34","author":[{"given":"Frank","family":"Siebenhaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bindslev-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurd","family":"Broesby-Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.iac.2014.01.012_bib1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.iac.2014.01.012_bib2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"10.1016\/j.iac.2014.01.012_bib3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.iac.2014.01.012_bib4","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jaci.2012.10.015","article-title":"Prevalence of indolent systemic mastocytosis in a Dutch region","volume":"131","author":"van Doormaal","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"15","key":"10.1016\/j.iac.2014.01.012_bib5","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1517\/14656566.2013.824424","article-title":"Mastocytosis: update on pharmacotherapy and future directions","volume":"14","author":"Cardet","year":"2013","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.iac.2014.01.012_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.iac.2013.09.001","article-title":"Mastocytosis","volume":"34","author":"Carter","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"2","key":"10.1016\/j.iac.2014.01.012_bib7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.iac.2014.01.012_bib8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jaci.2013.02.019","article-title":"KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis","volume":"132","author":"Broesby-Olsen","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2014.01.012_bib9","doi-asserted-by":"crossref","unstructured":"Alvarez-Twose I, Zanotti R, Gonzalez-de-Olano D, et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. 2014;133(2):520\u20138.","DOI":"10.1016\/j.jaci.2013.06.020"},{"issue":"9901","key":"10.1016\/j.iac.2014.01.012_bib10","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0140-6736(13)61605-0","article-title":"Anaphylaxis caused by mosquito allergy in systemic mastocytosis","volume":"382","author":"Reiter","year":"2013","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.iac.2014.01.012_bib11","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.iac.2014.01.012_bib12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s11882-013-0392-6","article-title":"Primary mast cell disorders in children","volume":"13","author":"Fried","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"issue":"2","key":"10.1016\/j.iac.2014.01.012_bib13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00105-011-2201-2","article-title":"Childhood-onset mastocytosis","volume":"63","author":"Siebenhaar","year":"2012","journal-title":"Hautarzt"},{"issue":"2","key":"10.1016\/j.iac.2014.01.012_bib14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000048187","article-title":"Cutaneous mastocytosis\u2013clinical heterogeneity","volume":"127","author":"Hartmann","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"10.1016\/j.iac.2014.01.012_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5070\/D30FK211ZH","article-title":"Cutaneous mastocytosis: two pediatric cases treated with topical pimecrolimus","volume":"16","author":"Correia","year":"2010","journal-title":"Dermatol Online J"},{"issue":"3","key":"10.1016\/j.iac.2014.01.012_bib16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0889-8588(05)70299-9","article-title":"Pediatric mastocytosis","volume":"14","author":"Hartmann","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"10.1016\/j.iac.2014.01.012_bib17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/bjh.12156","article-title":"Response of urticaria pigmentosa to cladribine in a patient with systemic mastocytosis","volume":"160","author":"Bennett","year":"2013","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.iac.2014.01.012_bib18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","article-title":"Tyrosine kinase inhibitors in the treatment of systemic mastocytosis","volume":"35","author":"Ustun","year":"2011","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.iac.2014.01.012_bib19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1046\/j.1523-1747.2003.12480.x","article-title":"Ultraviolet irradiation induces apoptosis in human immature, but not in skin mast cells","volume":"121","author":"Guhl","year":"2003","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2014.01.012_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/14628830050516614","article-title":"The treatment of urticaria pigmentosa with the frequency-doubled Q-switch Nd:YAG laser","volume":"2","author":"Bedlow","year":"2000","journal-title":"J\u00a0Cutan Laser Ther"},{"issue":"2","key":"10.1016\/j.iac.2014.01.012_bib21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1473-2165.2005.40205.x","article-title":"The cosmetic treatment of urticaria pigmentosa with Nd:YAG laser at 532 nanometers","volume":"4","author":"Resh","year":"2005","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"7","key":"10.1016\/j.iac.2014.01.012_bib22","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/all.12159","article-title":"Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial","volume":"68","author":"Siebenhaar","year":"2013","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.iac.2014.01.012_bib23","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jaci.2008.12.008","article-title":"High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study","volume":"123","author":"Siebenhaar","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.iac.2014.01.012_bib24","doi-asserted-by":"crossref","first-page":"e23931","DOI":"10.1371\/journal.pone.0023931","article-title":"H1-antihistamine up-dosing in chronic spontaneous urticaria: patients' perspective of effectiveness and side effects\u2013a retrospective survey study","volume":"6","author":"Weller","year":"2011","journal-title":"PloS One"},{"issue":"10","key":"10.1016\/j.iac.2014.01.012_bib25","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1398-9995.2009.02178.x","article-title":"EAACI\/GA(2)LEN\/EDF\/WAO guideline: management of urticaria","volume":"64","author":"Zuberbier","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2014.01.012_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.02.2011.3910","article-title":"Oral and topical sodium cromoglicate in the treatment of diffuse cutaneous mastocytosis in an infant","author":"Edwards","year":"2011","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1016\/j.iac.2014.01.012_bib27","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1365-2133.2009.09516.x","article-title":"Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus","volume":"162","author":"Vieira Dos Santos","year":"2010","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.iac.2014.01.012_bib28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1248\/bpb.16.375","article-title":"Absorption mechanism of 1,3-bis(2-ethoxycarbonylchromon-5-yloxy)-2-((S)-lysyloxy)propane dihydrochloride (N-556), a prodrug for the oral delivery of disodium cromoglycate","volume":"16","author":"Yoshimi","year":"1993","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"10.1016\/j.iac.2014.01.012_bib29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2222.1992.tb03102.x","article-title":"Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine","volume":"22","author":"Okayama","year":"1992","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1016\/j.iac.2014.01.012_bib30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.iac.2006.05.005","article-title":"Mast cell mediators in allergic inflammation and mastocytosis","volume":"26","author":"Castells","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"issue":"8602","key":"10.1016\/j.iac.2014.01.012_bib31","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0140-6736(88)90055-4","article-title":"Treatment of adult systemic mastocytosis with a PAF-acether antagonist BN52063","volume":"2","author":"Guinot","year":"1988","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.iac.2014.01.012_bib32","first-page":"391","article-title":"Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis","volume":"77","author":"Macpherson","year":"1989","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.iac.2014.01.012_bib33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1525-1470.2011.01576.x","article-title":"Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis","volume":"29","author":"Turner","year":"2012","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"10.1016\/j.iac.2014.01.012_bib34","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0889-8588(05)70298-7","article-title":"Gastrointestinal abnormalities and involvement in systemic mastocytosis","volume":"14","author":"Jensen","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"10.1016\/j.iac.2014.01.012_bib35","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jaci.2013.05.026","article-title":"Gastrointestinal manifestations in mastocytosis: a study of 83 patients","volume":"132","author":"Sokol","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2014.01.012_bib36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/187152806775269303","article-title":"Current options in the treatment of mast cell mediator-related symptoms in mastocytosis","volume":"5","author":"Escribano","year":"2006","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"7","key":"10.1016\/j.iac.2014.01.012_bib37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0145-2126(01)00046-7","article-title":"Mastocytosis: molecular mechanisms and clinical disease heterogeneity","volume":"25","author":"Metcalfe","year":"2001","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.iac.2014.01.012_bib38","doi-asserted-by":"crossref","first-page":"e39468","DOI":"10.1371\/journal.pone.0039468","article-title":"Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression","volume":"7","author":"Moura","year":"2012","journal-title":"PloS One"},{"issue":"10","key":"10.1016\/j.iac.2014.01.012_bib39","doi-asserted-by":"crossref","first-page":"e26375","DOI":"10.1371\/journal.pone.0026375","article-title":"Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy","volume":"6","author":"Moura","year":"2011","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.iac.2014.01.012_bib40","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00006842-198607000-00006","article-title":"Mixed organic brain syndrome as a manifestation of systemic mastocytosis","volume":"48","author":"Rogers","year":"1986","journal-title":"Psychosom Med"},{"issue":"9","key":"10.1016\/j.iac.2014.01.012_bib41","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJM197908303010903","article-title":"Oral disodium cromoglycate in the treatment of systemic mastocytosis","volume":"301","author":"Soter","year":"1979","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.iac.2014.01.012_bib42","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromolyn sodium in the management of systemic mastocytosis","volume":"85","author":"Horan","year":"1990","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2014.01.012_bib43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2125.1989.tb05339.x","article-title":"The effect of disodium cromoglycate and ketotifen on the excretion of histamine and N tau-methylimidazole acetic acid in urine of patients with mastocytosis","volume":"27","author":"Mallet","year":"1989","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.iac.2014.01.012_bib44","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00000421-199408000-00009","article-title":"Radiotherapy of refractory bone pain due to systemic mast cell disease","volume":"17","author":"Johnstone","year":"1994","journal-title":"Am J Clin Oncol"},{"issue":"3\u20134","key":"10.1016\/j.iac.2014.01.012_bib45","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.prostaglandins.2009.01.001","article-title":"Survey of aspirin administration in systemic mastocytosis","volume":"88","author":"Butterfield","year":"2009","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"3","key":"10.1016\/j.iac.2014.01.012_bib46","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0889-8588(05)70301-4","article-title":"Treatment of systemic mast cell disorders","volume":"14","author":"Worobec","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.1016\/j.iac.2014.01.012_bib47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000048189","article-title":"Mastocytosis: current treatment concepts","volume":"127","author":"Worobec","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"10.1016\/j.iac.2014.01.012_bib48","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/ard.2004.029116","article-title":"Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment","volume":"64","author":"Lim","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.iac.2014.01.012_bib49","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1398-9995.2009.02259.x","article-title":"Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient","volume":"65","author":"Douglass","year":"2010","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.iac.2014.01.012_bib50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.anai.2013.08.014","article-title":"Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis","volume":"111","author":"Matito","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.iac.2014.01.012_bib51","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2007.05.011","article-title":"Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy","volume":"120","author":"Siebenhaar","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.iac.2014.01.012_bib52","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iac.2014.01.012_bib53","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2010.05.043","article-title":"Successful treatment of idiopathic anaphylaxis in an adolescent","volume":"126","author":"Pitt","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2014.01.012_bib54","doi-asserted-by":"crossref","first-page":"75.e1","DOI":"10.1016\/j.amjmed.2012.07.018","article-title":"Bone complications of mastocytosis: a link between clinical and biological characteristics","volume":"126","author":"Guillaume","year":"2013","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.iac.2014.01.012_bib55","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bone.2011.07.004","article-title":"Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis","volume":"49","author":"Rossini","year":"2011","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.iac.2014.01.012_bib56","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","article-title":"High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis","volume":"67","author":"van der Veer","year":"2012","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.iac.2014.01.012_bib57","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jaci.2012.11.008","article-title":"Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients","volume":"132","author":"Hartmann","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2014.01.012_bib58","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jaci.2013.06.019","article-title":"Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis","volume":"132","author":"Rabenhorst","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2014.01.012_bib59","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000091172","article-title":"Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis","volume":"139","author":"Kushnir-Sukhov","year":"2006","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"10.1016\/j.iac.2014.01.012_bib60","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/all.12318","article-title":"Management of anaphylaxis: a systematic review","volume":"69","author":"Dhami","year":"2013","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.iac.2014.01.012_bib61","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: summary report\u2013Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2014.01.012_bib62","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1398-9995.2005.00785.x","article-title":"Epidemiology of life-threatening and lethal anaphylaxis: a review","volume":"60","author":"Moneret-Vautrin","year":"2005","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.iac.2014.01.012_bib63","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jaci.2003.11.033","article-title":"Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization","volume":"113","author":"Bohlke","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2014.01.012_bib64","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jaci.2008.09.043","article-title":"The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project","volume":"122","author":"Decker","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2014.01.012_bib65","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-2222.2004.01882.x","article-title":"Incidence of anaphylaxis with circulatory symptoms: a study over a 3-year period comprising 940,000 inhabitants of the Swiss Canton Bern","volume":"34","author":"Helbling","year":"2004","journal-title":"Clin Exp Allergy"},{"issue":"2 Pt 1","key":"10.1016\/j.iac.2014.01.012_bib66","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0091-6749(99)70392-1","article-title":"Epidemiology of anaphylaxis in Olmsted County: a population-based study","volume":"104","author":"Yocum","year":"1999","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2014.01.012_bib67","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S1081-1206(10)61086-1","article-title":"Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group","volume":"97","author":"Lieberman","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.iac.2014.01.012_bib68","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000083954","article-title":"Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes","volume":"136","author":"Florian","year":"2005","journal-title":"Int Arch Allergy Immunol"},{"issue":"10","key":"10.1016\/j.iac.2014.01.012_bib69","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/j.1365-2222.2007.02804.x","article-title":"Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)","volume":"37","author":"Gonzalez de Olano","year":"2007","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.iac.2014.01.012_bib70","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cea.12225","article-title":"High prevalence of anaphylaxis in patients with systemic mastocytosis\u2013a single-center experience","volume":"44","author":"Gulen","year":"2013","journal-title":"Clin Exp Allergy"},{"issue":"8","key":"10.1016\/j.iac.2014.01.012_bib71","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1398-9995.2009.02270.x","article-title":"IgE-mediated anaphylaxis to Hippobosca equina in a patient with systemic mastocytosis","volume":"65","author":"Matito","year":"2010","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.iac.2014.01.012_bib72","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jaci.2012.12.1578","article-title":"Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis","volume":"132","author":"van Anrooij","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2014.01.012_bib73","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jaci.2012.10.052","article-title":"Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis","volume":"131","author":"Alvarez-Twose","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2014.01.012_bib74","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1046\/j.1365-2133.1999.03214.x","article-title":"Mastocytosis associated with severe wasp sting anaphylaxis detected by elevated serum mast cell tryptase levels","volume":"141","author":"Biedermann","year":"1999","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.iac.2014.01.012_bib75","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-2222.2009.03436.x","article-title":"Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy","volume":"40","author":"Dugas-Breit","year":"2010","journal-title":"Clin Exp Allergy"},{"issue":"13","key":"10.1016\/j.iac.2014.01.012_bib76","first-page":"238","article-title":"Insect stings: clinical features and management","volume":"109","author":"Przybilla","year":"2012","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"10.1016\/j.iac.2014.01.012_bib77","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/ACI.0b013e32833b280c","article-title":"Mastocytosis and insect venom allergy","volume":"10","author":"Bonadonna","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2014.01.012_bib78","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2014.01.012_bib79","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1398-9995.2007.01604.x","article-title":"High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis","volume":"63","author":"Kontou-Fili","year":"2008","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.iac.2014.01.012_bib80","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1398-9995.2009.02045.x","article-title":"Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis","volume":"64","author":"Kontou-Fili","year":"2009","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.iac.2014.01.012_bib81","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.anai.2010.04.011","article-title":"Omalizumab monotherapy for bee sting and unprovoked \u201canaphylaxis\u201d in a patient with systemic mastocytosis and undetectable specific IgE","volume":"104","author":"Kontou-Fili","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.iac.2014.01.012_bib82","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jlb.67.2.135","article-title":"c-Kit and c-kit mutations in mastocytosis and other hematological diseases","volume":"67","author":"Boissan","year":"2000","journal-title":"J\u00a0Leukoc Biol"},{"issue":"14","key":"10.1016\/j.iac.2014.01.012_bib83","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.iac.2014.01.012_bib84","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2011-12-397588","article-title":"In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells","volume":"120","author":"Soucie","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.iac.2014.01.012_bib85","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.iac.2014.01.012_bib86","doi-asserted-by":"crossref","first-page":"e43090","DOI":"10.1371\/journal.pone.0043090","article-title":"Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis","volume":"7","author":"Traina","year":"2012","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.iac.2014.01.012_bib87","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1200\/JCO.2011.38.9973","article-title":"Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis","volume":"30","author":"Alvarez-Twose","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.iac.2014.01.012_bib88","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1182\/blood.V120.21.799.799","article-title":"KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: results of a planned interim analysis of the global CPKC412D2201 trial","volume":"120","author":"Gotlib","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.iac.2014.01.012_bib89","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.21894","article-title":"Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study","volume":"85","author":"Paul","year":"2010","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.iac.2014.01.012_bib90","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.coi.2009.09.010","article-title":"Are we ready to downregulate mast cells?","volume":"21","author":"Karra","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.iac.2014.01.012_bib91","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-1-4419-9533-9_9","article-title":"Down-regulation of mast cell responses through ITIM containing inhibitory receptors","volume":"716","author":"Karra","year":"2011","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.iac.2014.01.012_bib92","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fimmu.2012.00238","article-title":"Novel identified receptors on mast cells","volume":"3","author":"Migalovich-Sheikhet","year":"2012","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.iac.2014.01.012_bib93","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cellimm.2010.02.003","article-title":"Human mast cells express intracellular TRAIL","volume":"262","author":"Berent-Maoz","year":"2010","journal-title":"Cell Immunol"},{"issue":"26","key":"10.1016\/j.iac.2014.01.012_bib94","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1182\/blood-2008-08-175190","article-title":"Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs","volume":"114","author":"Aichberger","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2014.01.012_bib95","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/sj.cdd.4401537","article-title":"Proapoptotic Bcl-2 family member Bim is involved in the control of mast cell survival and is induced together with Bcl-XL upon IgE-receptor activation","volume":"12","author":"Alfredsson","year":"2005","journal-title":"Cell Death Differ"},{"issue":"9","key":"10.1016\/j.iac.2014.01.012_bib96","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1182\/blood-2007-02-073957","article-title":"The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells","volume":"110","author":"Ekoff","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.iac.2014.01.012_bib97","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0002-9440(10)63442-6","article-title":"Expression of Bcl-2 and Bcl-xL in cutaneous and bone marrow lesions of mastocytosis","volume":"163","author":"Hartmann","year":"2003","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.iac.2014.01.012_bib98","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.4049\/jimmunol.0903656","article-title":"The BH3-mimetic ABT-737 induces mast cell apoptosis in\u00a0vitro and in\u00a0vivo: potential for therapeutics","volume":"185","author":"Karlberg","year":"2010","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"10.1016\/j.iac.2014.01.012_bib99","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1189\/jlb.1112609","article-title":"The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells","volume":"95","author":"Peter","year":"2013","journal-title":"J\u00a0Leukoc Biol"},{"issue":"11","key":"10.1016\/j.iac.2014.01.012_bib100","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/exd.12247","article-title":"Dimethylfumarate induces apoptosis in human mast cells","volume":"22","author":"Forster","year":"2013","journal-title":"Exp Dermatol"},{"issue":"34","key":"10.1016\/j.iac.2014.01.012_bib101","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.2174\/138161211798357827","article-title":"Mast cells as targets of pimecrolimus","volume":"17","author":"Ma","year":"2011","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.iac.2014.01.012_bib102","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000316353","article-title":"Pimecrolimus induces apoptosis of mast cells in a murine model of cutaneous mastocytosis","volume":"153","author":"Ma","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"10.1016\/j.iac.2014.01.012_bib103","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1111\/j.1468-3083.2012.04689.x","article-title":"Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria","volume":"27","author":"Magerl","year":"2012","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.iac.2014.01.012_bib104","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/09546634.2012.671909","article-title":"Miltefosine: a novel treatment option for mast cell-mediated diseases","volume":"24","author":"Maurer","year":"2013","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.iac.2014.01.012_bib105","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/jid.2008.248","article-title":"Miltefosine inhibits human mast cell activation and mediator release both in\u00a0vitro and in\u00a0vivo","volume":"129","author":"Weller","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2014.01.012_bib106","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2133.2009.09434.x","article-title":"Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial","volume":"162","author":"Hartmann","year":"2010","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.iac.2014.01.012_bib107","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/blood-2008-11-189605","article-title":"Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit","volume":"117","author":"Gerbaulet","year":"2011","journal-title":"Blood"},{"issue":"3\u20134","key":"10.1016\/j.iac.2014.01.012_bib108","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.imbio.2007.10.017","article-title":"Mast cell functions in the innate skin immune system","volume":"213","author":"Metz","year":"2008","journal-title":"Immunobiology"},{"issue":"4","key":"10.1016\/j.iac.2014.01.012_bib109","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jaci.2007.11.013","article-title":"Mast cell-driven skin inflammation is impaired in the absence of sensory nerves","volume":"121","author":"Siebenhaar","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856114000137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856114000137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T21:35:11Z","timestamp":1716586511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856114000137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0889856114000137"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2014.01.012","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718363160.793524946","asserted-by":"object"}]},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}